Shopping Cart 0
Cart Subtotal
USD 0

Generics in Turkey

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics in Turkey

Summary

Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Turkish generics market had total revenues of USD 2.2bn in 2017, representing a compound annual growth rate (CAGR) of 16.4% between 2013 and 2017.

- Market consumption volume increased with a CAGR of 1.7% between 2013 and 2017, to reach a total of 58.7% in 2017.

- Despite being launched in 2003, the Health Transformation Program was intended to improve hospital infrastructure and utilize the latest technology. However, in late 2014, the first PPP project financially closed after an investment from Siemens.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey

- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the Turkey generics market by value in 2017?

- What will be the size of the Turkey generics market in 2022?

- What factors are affecting the strength of competition in the Turkey generics market?

- How has the market performed over the last five years?

- How large is Turkey's generics market in relation to its regional counterparts?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market volume 10

Market Segmentation 11

Geography segmentation 11

Market Outlook 12

Market value forecast 12

Market volume forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 20

Abdi Ibrahim Ilac Sanayi ve Ticaret AS 20

Deva Holding AS 21

Nobel Pharmaceuticals 24

Novartis AG 25

Macroeconomic Indicators 29

Country data 29

Methodology 31

Industry associations 32

Related MarketLine research 32

Appendix 33

About MarketLine 33


List Of Figure

List of Figures

Figure 1: Turkey generics market value: USD million, 2013-17

Figure 2: Turkey generics market volume: % of total pharma, 2013-17

Figure 3: Turkey generics market geography segmentation: % share, by value, 2017

Figure 4: Turkey generics market value forecast: USD million, 2017-22

Figure 5: Turkey generics market volume forecast: % of total pharma, 2017-22

Figure 6: Forces driving competition in the generics market in Turkey, 2017

Figure 7: Drivers of buyer power in the generics market in Turkey, 2017

Figure 8: Drivers of supplier power in the generics market in Turkey, 2017

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2017

Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2017

Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2017

Figure 12: Deva Holding AS: revenues & profitability

Figure 13: Deva Holding AS: assets & liabilities

Figure 14: Novartis AG: revenues & profitability

Figure 15: Novartis AG: assets & liabilities


List Of Table

List of Tables

Table 1: Turkey generics market value: USD million, 2013-17

Table 2: Turkey generics market volume: % of total pharma, 2013-17

Table 3: Turkey generics market geography segmentation: USD million, 2017

Table 4: Turkey generics market value forecast: USD million, 2017-22

Table 5: Turkey generics market volume forecast: % of total pharma, 2017-22

Table 6: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts

Table 7: Deva Holding AS: key facts

Table 8: Deva Holding AS: key financials (USD )

Table 9: Deva Holding AS: key financials (TL)

Table 10: Deva Holding AS: key financial ratios

Table 11: Nobel Pharmaceuticals: key facts

Table 12: Novartis AG: key facts

Table 13: Novartis AG: key financials (USD )

Table 14: Novartis AG: key financial ratios

Table 15: Turkey size of population (million), 2013-17

Table 16: Turkey gdp (constant 2005 prices, USD billion), 2013-17

Table 17: Turkey gdp (current prices, USD billion), 2013-17

Table 18: Turkey inflation, 2013-17

Table 19: Turkey consumer price index (absolute), 2013-17

Table 20: Turkey exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Generics, MarketLine, Turkey


Companies

Abdi Ibrahim Ilac Sanayi ve Ticaret AS

Deva Holding AS

Nobel Pharmaceuticals

Novartis AG